These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 26066646)
1. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. Chughlay MF; Kramer N; Werfalli M; Spearman W; Engel ME; Cohen K Syst Rev; 2015 Jun; 4():84. PubMed ID: 26066646 [TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. Chughlay MF; Kramer N; Spearman CW; Werfalli M; Cohen K Br J Clin Pharmacol; 2016 Jun; 81(6):1021-9. PubMed ID: 26757427 [TBL] [Abstract][Full Text] [Related]
3. Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial. ; Dear J Trials; 2019 Jan; 20(1):27. PubMed ID: 30621764 [TBL] [Abstract][Full Text] [Related]
4. Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF? Elliott TR; Symes T; Kannourakis G; Angus P BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26740270 [TBL] [Abstract][Full Text] [Related]
5. Risk prediction of hepatotoxicity in paracetamol poisoning. Wong A; Graudins A Clin Toxicol (Phila); 2017 Sep; 55(8):879-892. PubMed ID: 28447858 [TBL] [Abstract][Full Text] [Related]
6. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Moosa MS; Maartens G; Gunter H; Allie S; Chughlay MF; Setshedi M; Wasserman S; Stead DF; Hickman N; Stewart A; Sonderup M; Spearman CW; Cohen K Clin Infect Dis; 2021 Nov; 73(9):e3377-e3383. PubMed ID: 32845997 [TBL] [Abstract][Full Text] [Related]
7. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Niu H; Sanabria-Cabrera J; Alvarez-Alvarez I; Robles-Diaz M; Stankevičiūtė S; Aithal GP; Björnsson ES; Andrade RJ; Lucena MI Pharmacol Res; 2021 Feb; 164():105404. PubMed ID: 33359912 [TBL] [Abstract][Full Text] [Related]
8. Plasma paracetamol concentration at hospital presentation has a dose-dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Cairney DG; Beckwith HK; Al-Hourani K; Eddleston M; Bateman DN; Dear JW Clin Toxicol (Phila); 2016 Jun; 54(5):405-10. PubMed ID: 27108714 [TBL] [Abstract][Full Text] [Related]
9. N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. Sanabria-Cabrera J; Tabbai S; Niu H; Alvarez-Alvarez I; Licata A; Björnsson E; Andrade RJ; Lucena MI Front Pharmacol; 2022; 13():876868. PubMed ID: 35656297 [No Abstract] [Full Text] [Related]
11. Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. Nash E; Sabih AH; Chetwood J; Wood G; Pandya K; Yip T; Majumdar A; McCaughan GW; Strasser SI; Liu K Med J Aust; 2021 Sep; 215(6):261-268. PubMed ID: 34272737 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Hu J; Zhang Q; Ren X; Sun Z; Quan Q Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):594-9. PubMed ID: 25732608 [TBL] [Abstract][Full Text] [Related]
13. Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial). Morrison EE; Oatey K; Gallagher B; Grahamslaw J; O'Brien R; Black P; Oosthuyzen W; Lee RJ; Weir CJ; Henriksen D; Dear JW; EBioMedicine; 2019 Aug; 46():423-430. PubMed ID: 31311721 [TBL] [Abstract][Full Text] [Related]
16. Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury. Moosa MS; Russomanno G; Dorfman JR; Gunter H; Patel C; Costello E; Carr D; Maartens G; Pirmohamed M; Goldring C; Cohen K Br J Clin Pharmacol; 2023 Jun; 89(6):1844-1851. PubMed ID: 36639145 [TBL] [Abstract][Full Text] [Related]
17. N-Acetyl cysteine does not prevent liver toxicity from chronic low-dose plus subacute high-dose paracetamol exposure in young or old mice. Kane AE; Huizer-Pajkos A; Mach J; McKenzie C; Mitchell SJ; de Cabo R; Jones B; Cogger V; Le Couteur DG; Hilmer SN Fundam Clin Pharmacol; 2016 Jun; 30(3):263-75. PubMed ID: 26821200 [TBL] [Abstract][Full Text] [Related]
18. A prospective observational study of a novel 2-phase infusion protocol for the administration of acetylcysteine in paracetamol poisoning. Isbister GK; Downes MA; Mcnamara K; Berling I; Whyte IM; Page CB Clin Toxicol (Phila); 2016; 54(2):120-6. PubMed ID: 26691690 [TBL] [Abstract][Full Text] [Related]
19. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Sales I; Dzierba AL; Smithburger PL; Rowe D; Kane-Gill SL Ann Hepatol; 2013; 12(1):6-10. PubMed ID: 23293188 [TBL] [Abstract][Full Text] [Related]
20. Effect of treatment with prostaglandin E1 and N-acetylcysteine on pediatric liver transplant recipients: a single-center study. Bucuvalas JC; Ryckman FC; Krug S; Alonso MH; Balistreri WF; Kotagal U Pediatr Transplant; 2001 Aug; 5(4):274-8. PubMed ID: 11472606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]